Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman’s uterus for a range of genetic problems that can cause implantation failure, miscarriage and birth defects in a resulting child. Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:
- Preimplantation
genetic screening for abnormal chromosome number (PGT-A)
- Preimplantation
genetic testing for monogenic (individual) disease (PGT-M)
- Preimplantation
genetic testing structural rearrangement (PGT-SR) for known chromosomal
misarrangements such as inversion and translocation.
The report Preimplantation
Genetic Testing Market is projected to reach
USD 1.2 billion by 2028 from USD 0.7 billion in 2023, at a CAGR of 11.4% during
the forecast period.
The growth of Preimplantation genetic testing market
is majorly driven by the high risk of chromosomal abnormalities with advancing
maternal age, and the rising number of fertility clinics. Furthermore, the use
of fertility treatment options by single parents and same-sex couples is
expected to drive the growth of the preimplantation genetic testing market.
Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605
Key Growth Drivers:
1 Decline in fertility rates
2 Rise of fertility tourism in emerging economies
3 Increasing number of fertility clinics and IVF centers
4 Increasing public-private investments to develop novel diagnostic techniques.
5 High risk of chromosomal abnormalities with advancing
maternal age
Market Segmentation: -
Preimplantation
genetic screening, or aneuploidy screening, involves screening embryos for the
assessment of aneuploidy. This segment is expected to dominate the global
preimplantation genetic testing market during the forecast period, driven by a
decrease in female fertility with rising maternal age, better implantation rate
and reduced IVF cycle times.
By
end user, the global preimplantation genetic testing market is broadly
segmented into hospitals, diagnostic labs, fertility clinics, and other end
users. The large share of this segment can be attributed to factors such as the
increasing number of fertility centers globally, the high success rate of
treatment in fertility centers, and growing medical tourism in developing
countries.
Regional Analysis: -
Based
on the region, the preimplantation genetic testing market is segmented into
North America, Europe, Asia Pacific, and the Rest of the World. The North
American market is driven by high incidence of chromosomal disorders, and an
increasing number of awareness programs. Europe is the second-largest market
for the preimplantation genetic testing market due to the low fertility rates
and increasing maternal age in the region. Asia Pacific will observe high
growth during the forecast period with its growing medical tourism for
infertility treatment in the region’s countries.
Recent
Developments of Preimplantation Genetic Testing Industry
- In 2023, Thermo Fisher Scientific Inc.
(US) launched two new NGS-based test kits to support preimplantation
genetic testing-aneuploidy (PGT-A), commonly used in vitro fertilization
(IVF) and intracytoplasmic sperm injection (ICSI) research.
- In 2022, The Cooper Companies, Inc. (US)
released the addition of Parental QC, Genetic PN check, and Origin of
Aneuploidy to PGT-A testing as PGT-Complete.
- In 2021, Vitrolife (Sweden) acquired
Igenomix (Spain), a leader in reproductive genetic testing services
primarily for IVF clinics.
Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=605
Top key Players: -
Major
players in the preimplantation genetic testing market include Illumina, Inc.
(US), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US),
Revvity (US), and The Cooper Companies, Inc. (US).
No comments:
Post a Comment